Treatment of Chronic Pruritus through Intranasal or Intrathecal Delivery of Ruxolitinib or Tofacitinib (JAK inhibitors)
—
Value proposition: Novel approach to treat chronic itch through the intrathecal or intranasal delivery of JAK inhibitors.
Technology Description
Researchers at Washington University in St. Louis have developed a new method for treating chronic idiopathic pruritus (CIP) in both patients and m…
